ABSTRACT
Mitomycin has been associated with microangiopathic hemolytic anemia and renal failure. We describe a patient with the adult hemolytic-uremic syndrome due to mitomycin who was successfully treated with intense plasma exchange therapy and corticosteroid therapy. Patients receiving mitomycin should have their conditions monitored closely for acute renal failure, thrombocytopenia, and hemolytic anemia.
Subject(s)
Hemolytic-Uremic Syndrome/therapy , Mitomycins/adverse effects , Plasma Exchange , Prednisolone/therapeutic use , Adenocarcinoma/drug therapy , Female , Hemolytic-Uremic Syndrome/chemically induced , Humans , Middle Aged , Stomach Neoplasms/drug therapyABSTRACT
Cisplatin (cis-diamminedichloroplatinum), a chemotherapeutic agent active against solid tumors, is a known cause of acute renal failure and renal tubular dysfunction. We saw a case of renal magnesium wasting and hypomagnesemia in a 58-year-old woman with genital pelvic malignancy. Her initial manifestation was that of chronic symptomatic hypocalcemia of four months' duration. The relatively reduced parathyroid hormone level in this patient and the possible sites of cisplatin-induced renal tubular dysfunction resulting in hypermagnesuria were evaluated. This case emphasizes the importance of serially observing cisplatin-treated patients for the possible development of hypomagnesemic hypocalcemia.
